Atrium Therapeutics Inc
RNAHeld by 2 superinvestors.
SEC 10-K · fundamentals
Business quality
as of 2026-03-31- Revenue growth
- +1148.3%
- Net margin
- -84.7%
- ROE
- -7.1%
- FCF margin
- -169.3%
SEC 13F · holders
Superinvestors Holding This Security
2 holders · $3.3M combined · this quarter +2 opened / -0 exited
- Value$3.1MWeight (prev→now)New · 2.1%
- Value$206,486Weight (prev→now)New · 0.0%
SEC 13F · notes
Written summary
Written summary
Atrium Therapeutics Inc (RNA) is held by 2 of the superinvestors tracked on Compounder, with a combined $3.3M in reported 13F value. The largest position belongs to Paul Isaac, where it makes up 2.1% of the portfolio.
Other notable holders by value include Jeremy Grantham (0.0% of its book).
Over the latest quarter, 2 of the tracked filers opened a new position in RNA, 0 added to existing ones, 0 trimmed, and 0 sold out entirely.
Holder counts and values reflect the most recent SEC Form 13F filings, through the quarter ended 2026-03-31. Source: SEC EDGAR. A 13F shows only long US-listed positions and can lag the real portfolio by up to 45 days, so this is disclosed long ownership, not a complete picture.
SEC 13F · co-ownership
Also held by these investors
Investors holding Atrium Therapeutics Inc (RNA) also commonly hold →
- Microsoft CorpMSFT2 holders
- Alphabet Inc-Cl AGOOGL2 holders
- Devon Energy CorpDVN2 holders
- Corebridge Financial IncCRBG2 holders
- Mgic Investment CorpMTG2 holders
- B2gold CorpBTG2 holders
See which stocks look cheap against a conservative value band. Browse all valued stocks
Sources· SEC EDGAR 13F as of 2026-03-31 · filed 2026-05-14
Educational data only — not investment advice. 13F positions are self-reported and can lag up to 45 days.
Stay Updated
New-quarter 13F moves and valuation updates, to your inbox.